MetLife (MET) Stock Forecast & Price Target

$84.60 -3.43 (-3.90%)

Closing price 03:59 PM Eastern

Extended Trading

$84.82 +0.22 (+0.26%)

As of 07:36 PM Eastern

Compare

MetLife - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 14 Analyst Ratings

Sell
0

Hold
2

Buy
12

Based on 14 Wall Street analysts who have issued ratings for MetLife in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 14 analysts, 2 have given a hold rating, 11 have given a buy rating, and 1 has given a strong buy rating for MET.

Consensus Price Target

$95.62
13.02% Upside

According to the 14 analysts' twelve-month price targets for MetLife, the average price target is $95.62. The highest price target for MET is $103.00, while the lowest price target for MET is $88.00. The average price target represents a forecasted upside of 13.02% from the current price of $84.60.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for MET and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for MetLife and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MET Analyst Ratings Over Time

Type	Current Forecast 6/24/25 to 6/24/26	1 Month Ago 5/25/25 to 5/25/26	3 Months Ago 3/26/25 to 3/26/26	1 Year Ago 6/24/24 to 6/24/25
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	2 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	11 Buy rating(s)	11 Buy rating(s)	8 Buy rating(s)	11 Buy rating(s)
Hold	2 Hold rating(s)	2 Hold rating(s)	3 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$95.62	$95.15	$93.42	$94.17
Forecasted Upside	13.02% Upside	13.32% Upside	34.18% Upside	18.13% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

MET Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

MET Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

MetLife Stock vs. The Competition

Type	MetLife	Finance Companies	Broader Market
Consensus Rating Score	2.93	2.30	2.52
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	13.02% Upside	30.11% Upside	15.50% Upside
News Sentiment Rating	Neutral News See Recent MET News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
6/15/2026	Weiss Ratings 5 of 5 stars		Upgrade	Buy (B-) ➝ Buy (B)
5/26/2026	Piper Sandler 2 of 5 stars	John Barnidge 2 of 5 stars	Boost Target	Neutral	$81.00 ➝ $86.00	+2.42%
5/21/2026	Morgan Stanley 3 of 5 stars	Nigel Dally 2 of 5 stars	Boost Target	Overweight	$89.00 ➝ $93.00	+11.74%
5/13/2026	Keefe, Bruyette & Woods Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ryan Krueger Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$87.00 ➝ $98.00	+24.65%
5/12/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Wesley Carmichael Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$90.00 ➝ $95.00	+21.90%
5/12/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jimmy Bhullar Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$95.00 ➝ $96.00	+23.48%
5/8/2026	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Yaron Kinar Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$95.00	+22.06%
5/7/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Alex Scott Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$89.00 ➝ $93.00	+15.92%
4/14/2026	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joshua Shanker Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$103.00 ➝ $99.00	+29.81%
4/9/2026	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$96.00	+30.35%
VWAV: An Under-the-Radar Defense Play (Ad) VisionWave Holdings (NASDAQ: VWAV) is developing a multi-domain defense platform combining AI-powered analytics, RF sensing, advanced imaging, and autonomous technologies into a single intelligence ecosystem. With new patent filings, early commercial activity, and expanding platforms including xCalibre AI and DeepWave RF, VWAV is pursuing a comprehensive defense technology stack as global military modernization spending accelerates. Find out why VWAV deserves a place on your watchlist today
4/9/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Ward Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$98.00 ➝ $102.00	+36.56%
3/11/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Andrew Kligerman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$91.00 ➝ $88.00	+24.50%
9/16/2025	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Tracy Benguigui Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Strong-Buy
8/11/2025	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Suneet Kamath Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$100.00 ➝ $103.00	+35.08%
1/23/2025	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jack Matten Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Market Perform	$97.00	+13.09%
7/23/2024	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Buy	$83.00 ➝ $89.00	+18.26%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 09:13 PM ET.

Should I Buy MetLife Stock? MET Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, June 21, 2026. Please send any questions or comments about these MetLife pros and cons to contact@marketbeat.com.

MetLife
Bull Case

Here are some ways that investors could benefit from investing in MetLife, Inc.:

MetLife, Inc. recently reported earnings per share of $2.42, exceeding analyst expectations, which indicates strong financial performance and potential for future growth.
The company has a solid return on equity of 22.60%, suggesting effective management and profitability, which can be attractive to investors looking for efficient use of equity.
MetLife, Inc. has increased its quarterly dividend to $0.5925, reflecting a commitment to returning value to shareholders and indicating financial stability.
Analysts have a consensus price target of approximately $95.31 for MetLife, Inc., suggesting potential upside from the current stock price, which is around $90.
Recent expansion into new product offerings, such as a deferred-payment solution for non-physical injury claims, showcases MetLife, Inc.'s innovation and ability to adapt to market needs.

MetLife
Bear Case

Investors should be bearish about investing in MetLife, Inc. for these reasons:

The company's revenue of $14.18 billion fell short of analyst estimates, which may raise concerns about future growth and market competitiveness.
Despite a positive earnings report, MetLife, Inc. has a net margin of only 4.66%, indicating that profitability may be under pressure, which could affect long-term returns.
Some analysts have lowered their target prices for MetLife, Inc., which could signal a lack of confidence in the stock's short-term performance.
The payout ratio of 45.93% suggests that a significant portion of earnings is being distributed as dividends, which may limit funds available for reinvestment in growth opportunities.
Market sentiment can be volatile, and any negative news or economic downturns could disproportionately affect the financial services sector, including MetLife, Inc.

MET Forecast - Frequently Asked Questions

According to the research reports of 14 Wall Street equities research analysts, the average twelve-month stock price forecast for MetLife is $95.62, with a high forecast of $103.00 and a low forecast of $88.00.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MetLife in the last year. There are currently 2 hold ratings, 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" MET shares.

According to analysts, MetLife's stock has a predicted upside of 13.02% based on their 12-month stock forecasts.

Over the previous 90 days, MetLife's stock had 2 upgrades by analysts.

MetLife has been rated by research analysts at Bank of America, Barclays, Evercore, JPMorgan Chase & Co., Keefe, Bruyette & Woods, Mizuho, Morgan Stanley, Piper Sandler, UBS Group, Weiss Ratings, and Wells Fargo & Company in the past 90 days.

Analysts like MetLife more than other "finance" companies. The consensus rating for MetLife is Moderate Buy while the average consensus rating for "finance" companies is Hold. Learn more on how MET compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With MetLife Recommendations

This page (NYSE:MET) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MetLife (MET) Stock Forecast & Price Target

MetLife - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

MET Analyst Ratings Over Time

MET Analyst Recommendations By Month

MET Price Targets by Month

MetLife Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy MetLife Stock? MET Pros and Cons Explained

MetLife
Bull Case

MetLife
Bear Case

MET Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With MetLife Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MetLife (MET) Stock Forecast & Price Target

MetLife - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

MET Analyst Ratings Over Time

MET Analyst Recommendations By Month

MET Price Targets by Month

MetLife Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy MetLife Stock? MET Pros and Cons Explained

MetLife Bull Case

MetLife Bear Case

MET Forecast - Frequently Asked Questions

What is MetLife's forecast for 2026?

Should I buy or sell MetLife stock right now?

Does MetLife's stock price have much upside?

Has MetLife been upgraded by Wall Street analysts recently?

What analysts cover MetLife?

Do Wall Street analysts like MetLife more than its competitors?

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With MetLife Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

MetLife
Bull Case

MetLife
Bear Case